Drug development

#AI / data analytics / healthtech / informatics #Biotechnology #Database #Drug development #R&D #Research

Bridging the gap between R&D teams in biotechnology   

Ashu Singhal, President & Co-Founder of Benchling, shares newly heightened expectations for the biotechnology industry following the developments of the last 18 months.   The last 18 months have heightened expectations for the biotechnology industry. Scientists came together to develop vaccines at record speeds and set the… Read More

#News

#Biosciences #Cancer research #Drug development #Drug discovery #Oncology #Precision medicine

Anticancer Bioscience expands to Chinese biotech research park 

Anticancer Bioscience, a company developing synthetic lethal approaches to precision oncology, have relocated to Tianfu International Biotown, in Chengdu, China, to accommodate its growth and expansion, and on the back of its recent financing. Biotown is considered the premier biotech research park in Chengdu, the capital of Sichuan province.  The… Read More

#News

#Bipolar #Collaboration #Drug development #Pharmaceuticals

Partnership meets an unmet need for bipolar disorder patients 

Lo.Li. Pharma International has announced a new strategic partnering plan for its new product, Deplesin, which meets an unmet need for bipolar disorder (BD) patients. The discussions are underway with the aim of increasing accessibility to this novel adjunctive agent in the treatment of BD patients, who often experience a number… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Rare disease

Can real-world data transform the rare disease research landscape? 

Cytel and Pulse Infoframe have collaborated to create a solution that marks a new direction in research for rare disease. This partnership will support drug development sponsors seeking to implement real-world evidence solutions where the data generated can be used for a range of purposes, from synthetic controls and comparative effectiveness to… Read More

#News

#Drug development #Drug discovery #Healthcare #Library screening #Screening

TropIQ: Digitalising drug discovery for vector-borne diseases 

More than half of the world’s population is at risk from vector-borne diseases that are transmitted by insects such as mosquitoes, flies and ticks. These diseases cause more than one million deaths annually, and it is primarily people in the poorest countries who are the most vulnerable. Sophia Ktori shares insights fromTropIQ Health… Read More

#Editor's Choice #Exclusive Content #News

#Covid-19 #Drug development #Drug discovery

This week in drug discovery (6-10 December) 

News round-up by DDW’s Megan Thomas for 6-10 December  In the wake of the discovery of the Omicron Covid-19 variant globally, DDW’s Megan Thomas rounds up five news stories which show the strides being made to understand and fight this variant across the drug discovery industry. … Read More

#News

#Biotechnology #Clinical trials #Drug design #Drug development #Rare disease #Therapeutics

Inside the rare disease centre which aims to accelerate biotech growth 

Emmes has launched a rare disease centre, Orphan Reach, to combine its health research across the public sector and biopharmaceutical industry. DDW’s Megan Thomas spoke with Thomas Ogorka, Managing Director of Orphan Reach: Emmes’ Rare Disease Center, about its potential.  MT: What will the expanded Orphan Reach centre add to what Emmes already offers?   TO: First and foremost, specialised rare… Read More

#Exclusive Content #News #Opinion

#Collaboration #Drug development #Drug discovery #Genomics #Machine learning

GSK and Oxford University team up to unravel mechanisms of disease 

GlaxoSmithKline (GSK) and the University of Oxford have announced a five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine, which will be based at the University of Oxford and improve the success and speed of research and development of new medicines, building on insights from human… Read More

#News

MicroRNA
#Biopharmaceutical #Drug development #Pharmaceuticals #Therapeutics

Regulus appoints VP of chemistry and pharmaceutical development 

Regulus Therapeutics, a biopharmaceutical company focused on the discovery and development of medicines targeting microRNAs, has appointed Mohammad Ahmadian as Vice President of Chemistry and Pharmaceutical Development.   The role  In his role, Dr. Ahmadian will assist in managing research and development of the company’s drug… Read More

#News

#Biosciences #Drug development #Funding #RNA #Technology #Therapeutics

Sixfold Bioscience completes $10.5 million seed financing 

Sixfold Bioscience (Sixfold), a company using computation and advanced chemistry to design RNA therapeutic delivery systems, has raised $10.5 million in its seed funding round, which will support the continued development of the company’s Mergo RNA therapeutics delivery platform.  Investors   Investors in the seed round included Cantos Ventures, Y Combinator, Lombard Street… Read More

#Business & Investment #News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Omicron #Therapeutics

Breakthrough: New drug for Omicron and coronavirus strains 

Infex Therapeutics scientists have announced a breakthrough in laboratory trials of a new drug to treat Covid-19 and new variants of the disease, such as the Omicron variant.   Infex’s COV-X programme inhibits a new protease target that is responsible for viral replication across the broad spectrum of SARS-CoV-1, MERS-CoV and SARS-CoV-2. As such,… Read More

#Covid-19 #News #Trending News

#Drug development

Developing pain medication with fewer side effects 

Dr. Ken Ng, a professor at the University of Windsor and adjunct professor at the University of Calgary (UCalgary), and Sam Carr, a PhD student from UCalgary, have been working with Dr. Peter Facchini’s group at UCalgary to better understand how natural opiates are produced. The team has narrowed their focus on one… Read More

#News #Videos

#Clinical trials #Drug development #Software

Community forum and resource hub launched to support clinical trials 

Formedix, a provider of clinical trial software solutions, has launched the Formedix ryze Community to provide customers with a location to collaborate, expand their knowledge and share information.  What does the platform do?  Through a range of tools, the ryze Community will support the pharmaceutical industry to streamline and enhance… Read More

#News

#Clinical trials #Drug development

Data suggests racial diversity underrepresented in clinical trials 

Phesi has analysed protocol design data and showed that Asian, Hispanic and Latino, Native Americans and Alaska natives, Native Hawaiians and other Pacific Islander patient subpopulations were all significantly and consistently underrepresented over the decade. Black and African American patients appear to have become better represented over the past decade.  The study  The data was… Read More

#News #Trending News #Trends & Analysis

#Biotechnology #Drug development #Immunology / Virology & Vaccines #Microbiome #R&D

Sanofi acquisition is move for acne vaccine candidate 

Sanofi will acquire Origimm Biotechnology in December 2021, an Austrian biotechnology company specialising in the discovery of virulent skin microbiome components and antigens from bacteria-causing skin disease (such as acne), adding ORI-001 to Sanofi’s early-stage pipeline.  What is ORI-001?  ORI-001 is a therapeutic vaccine candidate for acne vulgaris based… Read More

#News

#Clinical trials #Drug development #Drug discovery #Tumours

FDA approves Avacta’s new cancer therapy drug

The US Food and Drug Administration (FDA) has approved Avacta’s Investigational New Drug (IND) application for AVA6000, which will allow the group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States.  What is AVA6000?  AVA6000 is a novel form of… Read More

#Cancer Research #News